Raltegravir Potassium
Brand name: Isentress
Rank #243 of 500 drugs by total cost
$53.0M
Total Cost
25,491
Total Claims
$53.0M
Total Cost
1,062
Prescribers
$2,081
Cost per Claim
489
Beneficiaries
26,662
30-Day Fills
$50K
Avg Cost/Provider
24
Avg Claims/Provider
About Raltegravir Potassium
Raltegravir Potassium (sold as Isentress) was prescribed 25,491 times by 1,062 Medicare Part D providers in 2023, costing the program $53.0M. At $2,081 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 240 | Dapaglifloz Propaned/Metformin (Xigduo Xr) | $54.4M | 58,629 |
| 241 | Buspirone Hcl (Buspirone Hcl) | $53.7M | 2,868,147 |
| 242 | Oxybutynin Chloride (Oxybutynin Chloride Er) | $53.4M | 1,872,901 |
| 243 | Raltegravir Potassium (Isentress) | $53.0M | 25,491 |
| 244 | Belumosudil Mesylate (Rezurock) | $52.3M | 2,280 |
| 245 | Pegloticase (Krystexxa) | $52.2M | 1,134 |
| 246 | Estrogens, Conjugated (Premarin) | $52.0M | 130,171 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology